mexiletine has been researched along with Amyotrophic Lateral Sclerosis in 6 studies
Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.
mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.
Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To collect preliminary data on the effects of mexiletine on cortical and axonal hyperexcitability in sporadic amyotrophic lateral sclerosis (ALS) in a phase 2 double-blind randomized controlled trial." | 9.41 | Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trial. ( Atassi, N; Brannagan, TH; Chen, IA; Cudkowicz, ME; Goutman, SA; Goyal, NA; Harms, MB; Kiernan, MC; Lacomis, D; Ladha, SS; Ma, M; Macklin, EA; McIlduff, CE; Rivner, MH; Rutkove, SB; Shefner, JM; Simmons, Z; Vucic, S; Wainger, BJ; Wang, LH; Weiss, MD; Zivkovic, S, 2021) |
| "To determine the safety and tolerability of mexiletine in a phase II double-blind randomized controlled trial of sporadic amyotrophic lateral sclerosis (SALS)." | 9.22 | A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression. ( Atassi, N; Barohn, RJ; Brown, RH; Cudkowicz, ME; Distad, JB; Graves, M; Greenblatt, DJ; Knox, AS; Macklin, EA; Parziale, N; Pestronk, A; Quinn, C; Salameh, JS; Shefner, JM; Simmons, Z; Swenson, A; Trivedi, J; Weiss, MD, 2016) |
| " Adverse events amounted 20% in the riluzole and 33% in the mexiletine groups." | 6.80 | A single blind randomized controlled clinical trial of mexiletine in amyotrophic lateral sclerosis: Efficacy and safety of sodium channel blocker phase II trial. ( Beppu, M; Fujimaki, Y; Hanaoka, H; Iwai, Y; Kimura, H; Kuwabara, S; Misawa, S; Mitsuma, S; Mizuno, T; Nakagawa, M; Noto, Y; Sato, Y; Sawaguchi, K; Sekiguchi, Y; Shibuya, K; Shimizu, T; Tsuji, Y; Watanabe, K, 2015) |
| "To collect preliminary data on the effects of mexiletine on cortical and axonal hyperexcitability in sporadic amyotrophic lateral sclerosis (ALS) in a phase 2 double-blind randomized controlled trial." | 5.41 | Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trial. ( Atassi, N; Brannagan, TH; Chen, IA; Cudkowicz, ME; Goutman, SA; Goyal, NA; Harms, MB; Kiernan, MC; Lacomis, D; Ladha, SS; Ma, M; Macklin, EA; McIlduff, CE; Rivner, MH; Rutkove, SB; Shefner, JM; Simmons, Z; Vucic, S; Wainger, BJ; Wang, LH; Weiss, MD; Zivkovic, S, 2021) |
| "To determine the safety and tolerability of mexiletine in a phase II double-blind randomized controlled trial of sporadic amyotrophic lateral sclerosis (SALS)." | 5.22 | A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression. ( Atassi, N; Barohn, RJ; Brown, RH; Cudkowicz, ME; Distad, JB; Graves, M; Greenblatt, DJ; Knox, AS; Macklin, EA; Parziale, N; Pestronk, A; Quinn, C; Salameh, JS; Shefner, JM; Simmons, Z; Swenson, A; Trivedi, J; Weiss, MD, 2016) |
| " Adverse events amounted 20% in the riluzole and 33% in the mexiletine groups." | 2.80 | A single blind randomized controlled clinical trial of mexiletine in amyotrophic lateral sclerosis: Efficacy and safety of sodium channel blocker phase II trial. ( Beppu, M; Fujimaki, Y; Hanaoka, H; Iwai, Y; Kimura, H; Kuwabara, S; Misawa, S; Mitsuma, S; Mizuno, T; Nakagawa, M; Noto, Y; Sato, Y; Sawaguchi, K; Sekiguchi, Y; Shibuya, K; Shimizu, T; Tsuji, Y; Watanabe, K, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Anger, T | 1 |
| Madge, DJ | 1 |
| Mulla, M | 1 |
| Riddall, D | 1 |
| Adiao, KJB | 1 |
| Espiritu, AI | 1 |
| Bagnas, MAC | 1 |
| Weiss, MD | 2 |
| Macklin, EA | 2 |
| McIlduff, CE | 1 |
| Vucic, S | 1 |
| Wainger, BJ | 1 |
| Kiernan, MC | 1 |
| Goutman, SA | 1 |
| Goyal, NA | 1 |
| Rutkove, SB | 1 |
| Ladha, SS | 1 |
| Chen, IA | 1 |
| Harms, MB | 1 |
| Brannagan, TH | 1 |
| Lacomis, D | 1 |
| Zivkovic, S | 1 |
| Ma, M | 1 |
| Wang, LH | 1 |
| Simmons, Z | 2 |
| Rivner, MH | 1 |
| Shefner, JM | 2 |
| Cudkowicz, ME | 2 |
| Atassi, N | 2 |
| Shibuya, K | 2 |
| Misawa, S | 2 |
| Kuwabara, S | 2 |
| Kimura, H | 1 |
| Noto, Y | 1 |
| Sato, Y | 1 |
| Sekiguchi, Y | 1 |
| Iwai, Y | 1 |
| Mitsuma, S | 1 |
| Beppu, M | 1 |
| Watanabe, K | 1 |
| Fujimaki, Y | 1 |
| Tsuji, Y | 1 |
| Shimizu, T | 1 |
| Mizuno, T | 1 |
| Nakagawa, M | 1 |
| Sawaguchi, K | 1 |
| Hanaoka, H | 1 |
| Knox, AS | 1 |
| Greenblatt, DJ | 1 |
| Graves, M | 1 |
| Parziale, N | 1 |
| Salameh, JS | 1 |
| Quinn, C | 1 |
| Brown, RH | 1 |
| Distad, JB | 1 |
| Trivedi, J | 1 |
| Barohn, RJ | 1 |
| Pestronk, A | 1 |
| Swenson, A | 1 |
2 reviews available for mexiletine and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Medicinal chemistry of neuronal voltage-gated sodium channel blockers.
Topics: Amyotrophic Lateral Sclerosis; Analgesics; Anticonvulsants; Epilepsy; Humans; Ion Channel Gating; Mo | 2001 |
Efficacy and safety of mexiletine in amyotrophic lateral sclerosis: a systematic review of randomized controlled trials.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Female; Humans; Male; Mexiletine; Middle Aged; Muscle Cr | 2020 |
3 trials available for mexiletine and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trial.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Axons; Cortical Excitability; Double-Blind Method; Elect | 2021 |
A single blind randomized controlled clinical trial of mexiletine in amyotrophic lateral sclerosis: Efficacy and safety of sodium channel blocker phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Amyotrophic Lateral Sclerosis; Animals; Dose-Response Relationship, | 2015 |
A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression.
Topics: Amyotrophic Lateral Sclerosis; Disease Progression; Dose-Response Relationship, Drug; Female; Follow | 2016 |
1 other study available for mexiletine and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
[Motor nerve hyperexcitability in ALS: its pathophysiology and treatment].
Topics: Amyotrophic Lateral Sclerosis; Cell Death; Humans; Mexiletine; Motor Neurons; Voltage-Gated Sodium C | 2014 |